Site-specifically 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 3, 2013, Pages 2562-2573

  Cheng, Qing ^a   Lu, Li ^a,b   Grafström, Jonas ^a   Hägg Olofsson, Maria ^a   Thorell, Jan Olov ^a,b   Samén, Erik ^a,b   Johansson, Katarina ^a   Ahlzén, Hanna Stina ^a   Linder, Stig ^a   Arnér, Elias S J ^a   Stone Elander, Sharon ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Annexin A5; Carbon 11; Cell death; Molecular imaging; Positron emission tomography; Sel tag

Indexed keywords

CALCIUM; CARBON 11; CYSTEINE; GLYCINE; LIPOCORTIN 5; RECOMBINANT PROTEIN; TETRAPEPTIDE; CARBON; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BIOLOGICAL MONITORING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG UPTAKE; DYNAMICS; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER CELL; MOLECULAR PROBE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN TARGETING; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CHEMISTRY; KINETICS; LIVER; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; RADIOGRAPHY; STAINING; SYNTHESIS;

MUS;

ANIMALS; ANNEXIN A5; APOPTOSIS; BASE SEQUENCE; BIOLOGICAL AVAILABILITY; CALCIUM; CARBON RADIOISOTOPES; ISOTOPE LABELING; KIDNEY; KINETICS; LIVER; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STAINING AND LABELING;

MLCS; MLOWN;

EID: 84872826265     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.12.007     Document Type: Article

References (59)

1. J. Czernin, W.A. Weber, and H.R. Herschman Molecular imaging in the development of cancer therapeutics Annu. Rev. Med. 57 2006 99 118
2. C.M. Gomes, A.J. Abrunhosa, P. Ramos, and E.K. Pauwels Molecular imaging with SPECT as a tool for drug development Adv. Drug Deliv. Rev. 63 2011 547 554
3. S.L. Pimlott, and A. Sutherland Molecular tracers for the PET and SPECT imaging of disease Chem. Soc. Rev. 40 2011 149 162
4. V. Brower Beyond FDG: many molecular imaging agents are in development J. Natl. Cancer Inst. 103 2011 13 15
5. A.M. Levin, and G.A. Weiss Optimizing the affinity and specificity of proteins with molecular display Mol. Biosyst. 2 2006 49 57
6. A. Rothe, R.J. Hosse, and B.E. Power In vitro display technologies reveal novel biopharmaceutics FASEB J. 20 2006 1599 1610
7. R.C. Ladner Polypeptides from phage display. A superior source of in vivo imaging agents Q. J. Nucl. Med. 43 1999 119 124
8. J.H. Lin Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies Curr. Drug Metab. 10 2009 661 691
9. A.M. Wu, and P.D. Senter Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 2005 1137 1146
10. 99mTc-labeled annexin V J. Nucl. Med. 45 2004 1536 1541
11. J.P. Holland, M.J. Williamson, and J.S. Lewis Unconventional nuclides for radiopharmaceuticals Mol. Imaging 9 2010 1 20
12. M. Pagani, S. Stone-Elander, and S.A. Larsson Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications Eur. J. Nucl. Med. 24 1997 1301 1327
13. M.H.M. Janssen, H.J.W.L. Aerts, M.C. Ollers, G. Bosmans, J.A. Lee, J. Buijsen, D. De Ruysscher, P. Lambin, G. Lammering, and A.L.A.J. Dekker Tumor delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients Int. J. Radiat. Oncol. Biol. Phys. 73 2009 456 465
14. L.K. Dunnwald, R.K. Doot, J.M. Specht, J.R. Gralow, G.K. Ellis, R.B. Livingston, H.M. Linden, V.K. Gadi, B.F. Kurland, E.K. Schubert, M. Muzi, and D.A. Mankoff PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake Clin. Cancer Res. 17 2011 2400 2409
15. V. Tolmachev, and S. Stone-Elander Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods Biochim. Biophys. Acta 1800 2010 487 510
16. Q. Cheng, L. Johansson, J.-O. Thorell, A. Fredriksson, E. Samén, S. Stone-Elander, and E.S.J. Arnér Selenolthiol and dithiol C-terminal tetrapeptide motifs for one-step purification and labeling of recombinant proteins produced in E. coli Chembiochem 7 2006 1976 1981
17. Q. Cheng, S. Stone-Elander, and E.S.J. Arnér Tagging recombinant proteins with a Sel-tag for purification, labeling with electrophilic compounds or radiolabeling with carbon-11 Nat. Protoc. 1 2006 604 613
18. L. Johansson, C. Chen, J.-O. Thorell, A. Fredriksson, S. Stone-Elander, G. Gafvelin, and E.S.J. Arnér Exploiting the 21st amino acid - purifying and labeling proteins by selenolate targeting Nat. Methods 1 2004 61 66
19. 11C-labeled Sel-tagged affibody molecule J. Nucl. Med. 53 2012 1446 1453
20. F.G. Blankenberg In vivo detection of apoptosis J. Nucl. Med. 49 Suppl. 2 2008 81S 95S
21. H.H. Boersma, B.L. Kietselaer, L.M. Stolk, A. Bennaghmouch, L. Hofstra, J. Narula, G.A. Heidendal, and C.P. Reutelingsperger Past, present, and future of annexin A5: from protein discovery to clinical applications J. Nucl. Med. 46 2005 2035 2050
22. K. Ohtsuki, K. Akashi, Y. Aoka, F.G. Blankenberg, S. Kopiwoda, J.F. Tait, and H.W. Strauss Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis Eur. J. Nucl. Med. 26 1999 1251 1258
23. J.R. Stratton, T.A. Dewhurst, S. Kasina, J.M. Reno, M.D. Cerqueira, D.G. Baskin, and J.F. Tait Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi Circulation 92 1995 3113 3121
24. F. Blankenberg To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy Clin. Cancer Res. 8 2002 2757 2758
25. T. Belhocine, N. Steinmetz, C. Li, A. Green, and F.G. Blankenberg The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility Technol. Cancer Res. Treat. 3 2004 23 32
26. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
27. J.L. Arias Drug targeting strategies in cancer treatment: an overview Mini. Rev. Med. Chem. 11 2011 1 17
28. P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26 2009 235 243
29. M.M. Schmidt, and K.D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8 2009 2861 2871
30. R. Huber, J. Romisch, and E.P. Paques The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes EMBO J. 9 1990 3867 3874
31. J. Ogasawara, R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata Lethal effect of the anti-Fas antibody in mice Nature 364 1993 806 809
32. 11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts PLoS One 7 2012 e42151
33. E.S.J. Arnér, H. Sarioglu, F. Lottspeich, A. Holmgren, and A. Böck High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes J. Mol. Biol. 292 1999 1003 1016
34. O. Rengby, L. Johansson, L.A. Carlson, E. Serini, A. Vlamis-Gardikas, P. Kårsnäs, and E.S.J. Arnér Assessment of production conditions for efficient use of Escherichia coli in high-yield heterologous recombinant selenoprotein synthesis Appl. Environ. Microbiol. 70 2004 5159 5167
35. P. Reichelt, C. Schwarz, and M. Donzeau Single step protocol to purify recombinant proteins with low endotoxin contents Protein Expr. Purif. 46 2006 483 488
36. W.P. Stemmer, and S.K. Morris Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis Biotechniques 13 1992 214 220
37. 11C]methane Appl. Radiat. Isot. 48 1997 153 157
38. P. D'Arcy, S. Brnjic, M.H. Olofsson, M. Fryknas, K. Lindsten, M. De Cesare, P. Perego, B. Sadeghi, M. Hassan, R. Larsson, and S. Linder Inhibition of proteasome deubiquitinating activity as a new cancer therapy Nat. Med. 17 2011 1636 1640
39. J.F. Tait, D.F. Gibson, and C. Smith Measurement of the affinity and cooperativity of annexin V-membrane binding under conditions of low membrane occupancy Anal. Biochem. 329 2004 112 119
40. J. Logan, D. Alexoff, and J.S. Fowler The use of alternative forms of graphical analysis to balance bias and precision in PET images J. Cereb. Blood Flow Metab. 31 2011 535 546
41. R.N. Gunn, A.A. Lammertsma, S.P. Hume, and V.J. Cunningham Parametric imaging of ligand-receptor binding in PET using a simplified reference region model NeuroImage 6 1997 279 287
42. M.A. Mintun, M.E. Raichle, M.R. Kilbourn, G.F. Wooten, and M.J. Welch A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography Ann. Neurol. 15 1984 217 227
43. C. Smith, R. Mehta, D.F. Gibson, Z. Levashova, F.G. Blankenberg, and J.F. Tait Characterization of a recombinant form of annexin VI for detection of apoptosis Bioconjug. Chem. 21 2010 1554 1558
44. J.F. Tait, C. Smith, and F.G. Blankenberg Structural requirements for in vivo detection of cell death wtih 99mTc-Annexin V J. Nucl. Med. 46 2005 807 815
45. J.F. Tait, C. Smith, Z. Levashova, B. Patel, F.G. Blankenberg, and J.L. Vanderheyden Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods J. Nucl. Med. 47 2006 1546 1553
46. F.G. Blankenberg, P.D. Katsikis, J.F. Tait, R.E. Davis, L. Naumovski, K. Ohtsuki, S. Kopiwoda, M.J. Abrams, M. Darkes, R.C. Robbins, H.T. Maecker, and H.W. Strauss In vivo detection and imaging of phosphatidylserine expression during programmed cell death Proc. Natl. Acad. Sci. U. S. A. 95 1998 6349 6354
47. 99mTc annexin V J. Nucl. Med. 40 1999 184 191
48. 99mTc-annexin A5 uptake and imaging to monitor chemosensitivity Methods Mol. Med. 111 2005 363 380
49. 99mTc-annexin A5 Br. J. Radiol. 76 2003 553 560
50. N. Sterin-Speziale, V.L. Kahane, C.P. Setton, M.C. Fernandez, and E.H. Speziale Compartmental study of rat renal phospholipid metabolism Lipids 27 1992 10 14
51. R. Matsuda, N. Kaneko, Y. Horikawa, F. Chiwaki, M. Shinozaki, T. Ieiri, T. Suzuki, and N. Ogawa Localization of annexin V in rat normal kidney and experimental glomerulonephritis Res. Exp. Med. (Berl) 200 2001 77 92
52. 3 for improved imaging of apoptosis in vivo Bioorg. Med. Chem. 18 2010 1356 1363
53. R. Matsuda, N. Kaneko, Y. Horikawa, F. Chiwaki, M. Shinozaki, S. Abe, W. Yumura, H. Nihei, and T. Ieiri Measurement of urinary annexin V by ELISA and its significance as a new urinary-marker of kidney disease Clin. Chim. Acta 298 2000 29 43
54. R. Weisiger, J. Gollan, and R. Ockner Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances Science 211 1981 1048 1051
55. 2 by annexin V in differentiated permeabilized HL-60 cells J. Biol. Chem. 272 1997 10474 10482
56. H. Kenis, H.R. Zandbergen, L. Hofstra, A.D. Petrov, E.A. Dumont, F.D. Blankenberg, N. Haider, N. Bitsch, M. Gijbels, J.W.H. Verjans, N. Narula, J. Narula, and C.P.M. Reutelingsperger Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging J. Nucl. Med. 51 2010 259 267
57. 89Zr-albumin as a model system J. Nucl. Med. 52 2011 625 633
58. 11C-labeled annexin V, for PET imaging of apoptosis J. Nucl. Med. 43 2002 362P
59. Q. Cheng, T. Sandalova, Y. Lindqvist, and E.S.J. Arnér Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1 J. Biol. Chem. 284 2009 3998 4008